Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
Quantum BioPharma (NASDAQ: QNTM) has engaged MZ Group to lead its strategic investor relations and financial communications program. MZ will develop and implement a comprehensive capital markets strategy to increase the company's visibility in the investment community.
The company is developing products focused on brain disorders and alcohol health, including unbuzzd™ and rekvry™, which address excessive alcohol use - a problem costing the U.S. approximately $249 billion annually. Additionally, Quantum is working on a potential first-in-class treatment for demyelinating diseases, including Multiple Sclerosis, which affects nearly 1 million people in the U.S. and 2.8 million worldwide.
The MZ engagement involves a two-month initial period at $10,000 per month, with automatic monthly renewals thereafter. The agreement can be terminated by either party with fifteen days' notice.
Quantum BioPharma (NASDAQ: QNTM) ha incaricato il MZ Group di guidare il programma strategico di relazioni con gli investitori e comunicazioni finanziarie. MZ svilupperà e implementerà una strategia completa per i mercati dei capitali al fine di aumentare la visibilità della società nella comunità degli investitori.
L'azienda sta sviluppando prodotti focalizzati sui disturbi cerebrali e sulla salute legata all'alcol, inclusi unbuzzd™ e rekvry™, che affrontano l'uso eccessivo di alcol, un problema che costa agli Stati Uniti circa 249 miliardi di dollari all'anno. Inoltre, Quantum sta lavorando a un trattamento potenzialmente innovativo per le malattie demielinizzanti, tra cui la sclerosi multipla, che colpisce quasi 1 milione di persone negli Stati Uniti e 2,8 milioni in tutto il mondo.
L'incarico del MZ prevede un periodo iniziale di due mesi a 10.000 dollari al mese, con rinnovi mensili automatici successivi. L'accordo può essere risolto da entrambe le parti con un preavviso di quindici giorni.
Quantum BioPharma (NASDAQ: QNTM) ha contratado al MZ Group para liderar su programa estratégico de relaciones con inversores y comunicaciones financieras. MZ desarrollará e implementará una estrategia integral de mercados de capitales para aumentar la visibilidad de la empresa en la comunidad de inversores.
La compañía está desarrollando productos enfocados en trastornos cerebrales y salud relacionada con el alcohol, incluidos unbuzzd™ y rekvry™, que abordan el consumo excesivo de alcohol, un problema que le cuesta a EE. UU. aproximadamente 249 mil millones de dólares anuales. Además, Quantum está trabajando en un tratamiento potencialmente innovador para enfermedades desmielinizantes, incluida la esclerosis múltiple, que afecta a casi 1 millón de personas en EE. UU. y 2.8 millones en todo el mundo.
El compromiso con MZ implica un período inicial de dos meses a 10,000 dólares al mes, con renovaciones automáticas mensuales después. El acuerdo puede ser terminado por cualquiera de las partes con un aviso de quince días.
Quantum BioPharma (NASDAQ: QNTM)는 MZ Group을 전략적 투자자 관계 및 재무 커뮤니케이션 프로그램의 주도적으로 참여하도록 하였습니다. MZ는 기업의 투자 커뮤니티 내 가시성을 높이기 위한 포괄적인 자본 시장 전략을 개발하고 시행할 것입니다.
회사는 뇌 질환과 알코올 건강에 초점을 맞춘 제품을 개발하고 있으며, 그 중 unbuzzd™와 rekvry™는 과도한 음주 문제를 해결합니다. 이 문제는 미국에 매년 약 2490억 달러의 비용을 초래하고 있습니다. 또한, Quantum은 다발성 경화증을 포함한 탈수초 질환에 대한 최초의 혁신적인 치료법을 개발하고 있으며, 이 질환은 미국에서 거의 100만 명, 전 세계적으로 280만 명에게 영향을 미치고 있습니다.
MZ와의 계약은 월 10,000달러로 2개월의 초기 기간을 포함하며, 이후 매월 자동 갱신됩니다. 계약은 어느 한 쪽도 15일 전에 통보하여 해지할 수 있습니다.
Quantum BioPharma (NASDAQ: QNTM) a engagé le MZ Group pour diriger son programme stratégique de relations avec les investisseurs et de communications financières. MZ développera et mettra en œuvre une stratégie complète pour les marchés des capitaux afin d'accroître la visibilité de l'entreprise au sein de la communauté des investisseurs.
La société développe des produits axés sur les troubles cérébraux et la santé liée à l'alcool, y compris unbuzzd™ et rekvry™, qui s'attaquent à l'usage excessif d'alcool, un problème qui coûte aux États-Unis environ 249 milliards de dollars par an. De plus, Quantum travaille sur un traitement potentiellement innovant pour les maladies démyélinisantes, y compris la sclérose en plaques, qui touche près d'1 million de personnes aux États-Unis et 2,8 millions dans le monde.
L'engagement avec MZ implique une période initiale de deux mois à 10 000 dollars par mois, avec des renouvellements mensuels automatiques par la suite. Le contrat peut être résilié par l'une ou l'autre des parties avec un préavis de quinze jours.
Quantum BioPharma (NASDAQ: QNTM) hat die MZ Group beauftragt, das strategische Investor Relations- und Finanzkommunikationsprogramm zu leiten. MZ wird eine umfassende Kapitalmarktstrategie entwickeln und implementieren, um die Sichtbarkeit des Unternehmens in der Investoren-Community zu erhöhen.
Das Unternehmen entwickelt Produkte, die sich auf Gehirnerkrankungen und Alkoholgesundheit konzentrieren, darunter unbuzzd™ und rekvry™, die übermäßigen Alkoholkonsum angehen - ein Problem, das den USA jährlich etwa 249 Milliarden Dollar kostet. Darüber hinaus arbeitet Quantum an einer potenziell bahnbrechenden Behandlung für demyelinisierende Erkrankungen, einschließlich der Multiplen Sklerose, die fast 1 Million Menschen in den USA und 2,8 Millionen weltweit betrifft.
Der MZ-Vertrag umfasst einen zwei-monatigen Anfangszeitraum zu 10.000 Dollar pro Monat, mit anschließenden automatischen Monatsverlängerungen. Der Vertrag kann von beiden Parteien mit einer Frist von fünfzehn Tagen gekündigt werden.
- Targeting large market opportunities: $249 billion annual cost of excessive drinking in the U.S.
- Addressing significant medical needs with 2.8 million MS patients worldwide
- Development of potentially first-in-class treatment for demyelinating diseases
- Monthly expenditure of $10,000 for IR services adds to operational costs
TORONTO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced it has retained the services of MZHCI, LLC, an MZ Group Company (“MZ”), to lead a comprehensive strategic investor relations and financial communications program across all key markets.
MZ will work closely with Quantum BioPharma management to develop and implement a comprehensive capital markets strategy designed to increase the Company’s visibility throughout the investment community. The campaign will highlight how Quantum BioPharma is developing a robust pipeline of products and assets focused on addressing significant unmet needs in brain disorders and alcohol health.
Chris Tyson, Executive Vice President at MZ North America, commented, "unbuzzd™ and rekvry™ utilize revolutionary technology that address the issue of excessive alcohol use. The National Institute of Health found that binge drinking rates among adults aged 35–50 reached an all-time high in 2023, and the CDC reports that excessive drinking costs the U.S. about
“Quantum BioPharma is also focused on a potential first-in-class approach to treating demyelinating diseases. Multiple sclerosis (“MS”) is characterized by demyelination, one of a group of disorders characterized by the destruction of myelin, the protective sheath that surrounds nerve fibers in the central nervous system. Almost 1 million people in the U.S. alone have been diagnosed with MS and 2.8 million people worldwide, according to the National Multiple Sclerosis Society.
“Led by a world-class research and development team and seasoned commercial experts, these life-changing and exciting opportunities in brain disorders and alcohol health represent a tremendous revenue potential, and we look forward to sharing the Quantum BioPharma story with our network of institutional, family offices and retail investors,” Mr. Tyson concluded.
For more information on Quantum BioPharma, please visit www.quantumbiopharma.com. To schedule a conference call with management, please email your request to QNTM@mzgroup.us or call Chris Tyson at 949-491-8235.
Management has made this decision following a thorough review of capital on hand and allocated resources to MZ to conduct Investor Relations Activities (as defined in the policies of the Canadian Securities Exchange) on its behalf.
About the MZ Engagement
Chris Tyson, Executive Vice President at MZ North America, along with Directors Larry Holub and Brooks Hamilton, will advise Quantum BioPharma's investor relations team in all facets of investor relations, including, but not limited to, the coordination of roadshows and investment conferences across key cities and building brand awareness with financial and social media outlets.
MZ is based in California and has been engaged for an initial period of two months (the “MZ Initial Period”), for US
About MZ
MZ North America is the US division of MZ Group, a global leader in investor relations with over 250 employees and 800 clients across 12 different exchanges. For over 25 years, MZ has implemented award winning programs and developed a reputation for delivering tangible results for public and private companies via strategic communications, industry-leading investor outreach, public relations, a market intelligence desk, and a suite of technology solutions, spanning websites, conference call/webcasting, video production and XBRL/Edgar filing services. MZ maintains a global footprint with professionals located throughout every time zone in North America, as well as Taipei and São Paulo. For more information, please visit www.mzgroup.us.
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of
Forward Looking Information
This press release contains certain “forward-looking statements” within the meaning of applicable Canadian securities law. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, identified by words or phrases such as “believes”, “anticipates”, “expects”, “is expected”, “scheduled”, “estimates”, “pending”, “intends”, “plans”, “forecasts”, “targets”, or “hopes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “will”, “should” “might”, “will be taken”, or “occur” and similar expressions) are not statements of historical fact and may be forward-looking statements. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company’s focus on the research and development of Lucid-MS to prevent and reverse myelin degradation; the Company’s Lucid-21-302 clinical development program in multiple sclerosis advancing towards human phase-2 efficacy trials; the Company’s intention to retain
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company’s assessment of market conditions, its ability to gain market share, and its potential competitive edge are accurate; the Company will have the ability to carry out its plans with respect to its new innovation and offerings, including its ability to conduct research and development of Lucid-MS; the Company’s Lucid-21-302 clinical development program in multiple sclerosis will advance towards human phase-2 efficacy trials; the Company will retain
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company’s inability to retain
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
QNTM@mzgroup.us
www.mzgroup.us
FAQ
What is the market size for Quantum BioPharma's (QNTM) alcohol-related products?
How many people could benefit from QNTM's Multiple Sclerosis treatment?
What is the cost of QNTM's new investor relations program with MZ Group?
What products is Quantum BioPharma (QNTM) developing?
